Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Prior treatment

• Lack of Exposure: Patients who never actually received iruplinalkib or took only a trivial amount (e.g., \< 1 week/cycle) before withdrawal for non-medical reasons.
• Confounding: Participation in another interventional clinical trial involving an investigational anti-tumor drug concurrently.
• Data Quality: Missing critical medical records that preclude assessment of primary endpoints (e.g., unknown start date, unknown prior therapy).

Other illness

• Wrong Diagnosis: Active malignancy of other histological types (excluding treated basal cell carcinoma, etc.).

Other

• Pregnancy: Pregnant or breastfeeding women.

• Population: Male or female patients aged ≥18 years.
• Diagnosis: Histologically or cytologically confirmed advanced lung adenocarcinoma.
• Molecular Status: Documentation of ALK rearrangement confirmed by a validated test (e.g., NGS, IHC, FISH).
• Prior Therapy: Prior treatment with lorlatinib (in any line of therapy), with documented disease progression or intolerance.
• Current Therapy: Initiated treatment with iruplinalkib in the real-world setting.
• Measurability: Presence of at least one evaluable lesion (measurable or non-measurable) for response assessment.
• Data Availability: availability of key clinical data (baseline characteristics, treatment history, and follow-up outcomes).